GeneFerm Biotechnology Co. Ltd. Statistics
GeneFerm Biotechnology Co. Ltd. (1796) Stock Statistics & Valuation Metrics
Total Valuation
GeneFerm Biotechnology Co. Ltd. has a market cap or net worth of TWD 1.10B. The enterprise value is TWD 1.35B.
- Market Cap
- TWD 1.10B
- Enterprise Value
- TWD 1.35B
Share Statistics
GeneFerm Biotechnology Co. Ltd. has 41,459,793 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 41,459,793
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
GeneFerm Biotechnology Co. Ltd.’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 3.30%.
- Return on Equity (ROE)
- 0.04
- Return on Assets (ROA)
- 0.02
- Return on Invested Capital (ROIC)
- 3.30%
- Return on Capital Employed (ROCE)
- 0.04
- Revenue Per Employee
- 2.35M
- Profits Per Employee
- 100.22K
- Employee Count
- 288
- Asset Turnover
- 0.53
- Inventory Turnover
- 2.56
Valuation Ratios
The current PE Ratio of GeneFerm Biotechnology Co. Ltd. is 68.59. GeneFerm Biotechnology Co. Ltd.’s PEG ratio is 0.03.
- PE Ratio
- 68.59
- PS Ratio
- 1.77
- PB Ratio
- 1.50
- Price to FCF
- 15.09
- Price to Operating Cash Flow
- 10.65
- PEG Ratio
- 0.03
Income Statement
In the last 12 months, GeneFerm Biotechnology Co. Ltd. had revenue of 677.10M and earned 28.86M in profits. Earnings per share was 0.70.
- Revenue
- 677.10M
- Gross Profit
- 190.80M
- Operating Income
- 46.04M
- Pretax Income
- 34.70M
- Net Income
- 28.86M
- EBITDA
- 115.40M
- Earnings Per Share (EPS)
- 0.70
Cash Flow
In the last 12 months, operating cash flow was 110.78M and capital expenditures -32.63M, giving a free cash flow of 78.15M billion.
- Operating Cash Flow
- 110.78M
- Free Cash Flow
- 78.15M
- Free Cash Flow per Share
- 1.88
Dividends & Yields
GeneFerm Biotechnology Co. Ltd. pays an annual dividend of ―, resulting in a dividend yield of 2.63%
- Dividend Per Share
- ―
- Dividend Yield
- 2.63%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 7.01%
- Earnings Yield
- 1.53%
Stock Price Statistics
- Beta
- 0.18
- 52-Week Price Change
- -47.02%
- 50-Day Moving Average
- 28.98
- 200-Day Moving Average
- 34.14
- Relative Strength Index (RSI)
- 32.59
- Average Volume (3m)
- 19.61K
Important Dates
GeneFerm Biotechnology Co. Ltd. upcoming earnings date is May 13, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- May 13, 2027
- Ex-Dividend Date
- ―
Financial Position
GeneFerm Biotechnology Co. Ltd. as a current ratio of 3.75, with Debt / Equity ratio of 39.70%
- Current Ratio
- 3.75
- Quick Ratio
- 2.55
- Debt to Market Cap
- 0.12
- Net Debt to EBITDA
- 0.38
- Interest Coverage Ratio
- 7.40
Taxes
In the past 12 months, GeneFerm Biotechnology Co. Ltd. has paid 5.83M in taxes.
- Income Tax
- 5.83M
- Effective Tax Rate
- 0.17
Enterprise Valuation
GeneFerm Biotechnology Co. Ltd. EV to EBITDA ratio is 11.80, with an EV/FCF ratio of 14.66.
- EV to Sales
- 1.72
- EV to EBITDA
- 11.80
- EV to Free Cash Flow
- 14.66
- EV to Operating Cash Flow
- 10.35
Balance Sheet
GeneFerm Biotechnology Co. Ltd. has TWD 281.97M in cash and marketable securities with TWD 312.78M in debt, giving a net cash position of -TWD 30.81M billion.
- Cash & Marketable Securities
- TWD 281.97M
- Total Debt
- TWD 312.78M
- Net Cash
- -TWD 30.81M
- Net Cash Per Share
- -TWD 0.74
- Tangible Book Value Per Share
- TWD 18.89
Margins
Gross margin is 25.22%, with operating margin of 2.97%, and net profit margin of 2.57%.
- Gross Margin
- 25.22%
- Operating Margin
- 2.97%
- Pretax Margin
- 3.16%
- Net Profit Margin
- 2.57%
- EBITDA Margin
- 14.60%
- EBIT Margin
- 3.58%
Analyst Forecast
The average price target for GeneFerm Biotechnology Co. Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 7.05%
- EPS Growth Forecast
- ―
